In a report released yesterday, Cory Kasimov from J.P. Morgan assigned a Hold rating to Acorda Therapeutics (NASDAQ: ACOR). The company’s shares closed yesterday at $24.55.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 3.5% and a 42.1% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Jounce Therapeutics Inc, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Acorda Therapeutics is a Hold with an average price target of $25.40, a 3.5% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Hold rating to the stock with a $21 price target.
.
See today’s analyst top recommended stocks >>
Based on Acorda Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.2 million. In comparison, last year the company had a GAAP net loss of $8.2 million.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.
